Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness of Lopinavir/Ritonavir in HIV Infected Infants

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria~* HIV infected~* Viral load greater than 10,000 copies/ml within 30 days prior to study entry~* Weigh more than 5.5 lbs at the time of enrollment~* Agree to take 2 nucleoside reverse transcriptase inhibitors (NRTIs) in addition to LPV/RTV~* Have consent of parent or guardian willing to provide signed informed consent and to have the infant followed at a PACTG site~Exclusion Criteria~* Currently taking a nonnucleoside reverse transcriptase inhibitor or protease inhibitor (PI) while on study~* Previously used LPV/RTV. Patients who were treated previously with other PIs are not excluded. Prior or concurrent maternal treatment with LPV/RTV is not excluded.~* For patients less than 6 weeks old at time of enrollment, less than 34 weeks gestation at delivery OR for patients 6 or more weeks old at time of enrollment, less than 32 weeks gestation at delivery~* Any laboratory toxicity of Grade 3 or greater. Hyperlipasemia of Grade 2 or higher is also excluded.~* Newly diagnosed acute opportunistic or serious bacterial infection requiring therapy at the time of enrollment~* Chemotherapy for active cancer~* Certain medications~* Any other clinically significant conditions, other than HIV infection, that would interfere with the study

- Gender: ALL
- Minimum Age: 14 Days
- Maximum Age: 6 Months
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).